Abstract
Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection. The cumulative knowledge on pharmacokinetics/ pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug monitoring (TDM) in patient care. However, logistical problems related to conventional sampling limit the application of TDM in research-oriented institutions. Dried blood spot (DBS) compared with conventional venous blood sampling has the advantages of easier sampling, storage and transportation, thus enabling the application of TDM even in remote areas. In addition, DBS with its lower biohazardous risk can be safely performed in a high HIV prevalence area, which also tends to have a high TB burden. Another benefit of DBS sampling is that it requires a smaller blood volume than conventional sampling and is highly recommended for application in pediatric TB. A limitation of DBS is that additional considerations are required for analysis method development and validation. The accuracy of the DBS method is influenced by a number of factors that need to be thoroughly examined in method development and validation. Further, the agreement between DBS and plasma/serum concentrations is not always understood and further investigations are required.
Keywords: Dried blood spot, tuberculosis, optimization, biohazards, malabsorption, rifabutin, isoniazid, ethambutol, hemoglobin, venous plasma
Current Pharmaceutical Design
Title: Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Volume: 17 Issue: 27
Author(s): D. H. Vu, J. W.C. Alffenaar, P. M. Edelbroek, J. R.B.J. Brouwers and D. R.A. Uges
Affiliation:
Keywords: Dried blood spot, tuberculosis, optimization, biohazards, malabsorption, rifabutin, isoniazid, ethambutol, hemoglobin, venous plasma
Abstract: Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection. The cumulative knowledge on pharmacokinetics/ pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug monitoring (TDM) in patient care. However, logistical problems related to conventional sampling limit the application of TDM in research-oriented institutions. Dried blood spot (DBS) compared with conventional venous blood sampling has the advantages of easier sampling, storage and transportation, thus enabling the application of TDM even in remote areas. In addition, DBS with its lower biohazardous risk can be safely performed in a high HIV prevalence area, which also tends to have a high TB burden. Another benefit of DBS sampling is that it requires a smaller blood volume than conventional sampling and is highly recommended for application in pediatric TB. A limitation of DBS is that additional considerations are required for analysis method development and validation. The accuracy of the DBS method is influenced by a number of factors that need to be thoroughly examined in method development and validation. Further, the agreement between DBS and plasma/serum concentrations is not always understood and further investigations are required.
Export Options
About this article
Cite this article as:
H. Vu D., W.C. Alffenaar J., M. Edelbroek P., R.B.J. Brouwers J. and R.A. Uges D., Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470174
DOI https://dx.doi.org/10.2174/138161211797470174 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry Structural and Binding Properties of the Active Cell Wall Hydrolase RipA from <i>M. tuberculosis</i>, a Promising Biosensing Molecule for Early Warning Bacterial Detection
Current Medicinal Chemistry Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry Safer, Greener, and More Facile Alternatives for Synthesis with Organic Azides
Current Organic Synthesis General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation
Current Pharmacogenomics and Personalized Medicine Synthesis and Antimicrobial Activity of Adamantyl Substituted Pyridoxine Derivatives
Letters in Drug Design & Discovery Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates
Current Drug Discovery Technologies Editorial [Hot Topic: Carbonic Anhydrases: Again, and Again, and Again (Executive Editor: Claudiu T. Supuran)]
Current Pharmaceutical Design Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Anti-Inflammatory Trends of 1, 3-Diphenyl-2-propen-1-one Derivatives
Mini-Reviews in Medicinal Chemistry Prevalence of Latent Tuberculosis (LTB) Among Pregnant Women in a High Burden Setting in Sudan using Interferon Gamma (IFN- γ) Releasing Assay (IGRA)
Current Women`s Health Reviews A Review on Genus Alseodaphne: Phytochemistry and Pharmacology
Mini-Reviews in Organic Chemistry Antimicrobial Compounds from Marine Invertebrates-Derived Microorganisms
Current Medicinal Chemistry Synthesis, In silico and Biological Studies of Thiazolyl-2h-chromen-2-one Derivatives as Potent Antitubercular Agents
Current Computer-Aided Drug Design Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Comprehensive View on Metabolic Pathway Analysis Methodologies
Current Bioinformatics The Role of Electrospinning in the Emerging Field of Nanomedicine
Current Pharmaceutical Design Reducing the Development of Antibiotic Resistance in Critical Care Units
Current Pharmaceutical Biotechnology The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design